JPMorgan raised the firm’s price target on Argenx (ARGX) to $925 from $830 and keeps an Overweight rating on the shares.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Promising Outlook for arGEN X: Robust Sales Projections and Strategic Expansion Drive Positive Risk-Reward Balance
- Denali says chief medical officer Carole Ho to depart to join Eli Lilly
- Argenx announces Health Canada approval of Vyvgart in CIDP
- Argenx price target raised to $930 from $820 at Piper Sandler
- Argenx price target raised to EUR 675 from EUR 655 at Deutsche Bank